Tidal Investments LLC Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Tidal Investments LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 38.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,223 shares of the medical equipment provider’s stock after buying an additional 5,872 shares during the period. Tidal Investments LLC’s holdings in Hologic were worth $1,530,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC increased its stake in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC increased its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Smithfield Trust Co increased its stake in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in Hologic in the fourth quarter valued at approximately $49,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of HOLX opened at $54.28 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $12.10 billion, a PE ratio of 17.12, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company’s 50 day simple moving average is $58.17 and its 200-day simple moving average is $66.61. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned $1.03 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In related news, Director Martin D. Madaus purchased 5,445 shares of the firm’s stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now directly owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.88% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of several recent analyst reports. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Finally, Morgan Stanley dropped their price target on shares of Hologic from $77.00 to $65.00 and set an “equal weight” rating on the stock in a research note on Monday, May 5th. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.